Bharat Biotech – India Chron

AIIMS Delhi to start second dose trial of Bharat Biotech’s Covaxin on 2-6 years old children by next week

Himanjali Mahanta — Fri, 23 Jul 2021 09:31:04 +0000

All India Institute of Medical Sciences (AIIMS) in New Delhi will commence the second dose trial of Bharat Biotech’s COVID-19 vaccine, Covaxin, for children aged 2-6 years.

According to ANI reports, sources on Thursday revealed that as part of its COVID-19 vaccination trials for children, Bharat Biotech is likely to administer the second phase dose of Covaxin to children aged between 2 and 6 years next week.

Sources also revealed that the children, in the above-mentioned age group, have already received the first dose of the COVID-19 vaccine.

AIIMS Delhi is one of the trial centres for the vaccine for those below 18 years. The sources added that the second dose of Covaxin has already been administered to children in the age group of 6-12 years at AIIMS, Delhi.

Additionally, the results of the clinical trials are expected to come in one month after the completion of trials of all age groups. The trial is being conducted in three phases by segregating children into categories according to their age.

The first trial was started in the age group of 12-18 years followed by the age group of 6-12 years and 2-6 years which are currently undergoing trials.

Recently, the Centre informed the Delhi High Court those clinical trials of COVID-19 vaccines for children under 18 years of age were to get completed soon.

Covaxin is 77.8% effective, gives 65.2% Protection against Delta variant, says Bharat Biotech

Himanjali Mahanta — Sat, 03 Jul 2021 08:09:39 +0000

Phase-III trials of Covaxin, made by Hyderabad’s Bharat Biotech, showed it was 93.4% effective against severe symptomatic Covid-19, the firm claimed on Saturday.

The data demonstrated 65.2% protection against the Delta variant, first identified in India. The Delta variant had led to a surge in infections in April and May, and the world’s highest daily death tolls.

It further showed effectiveness of an 77.8% against symptomatic Covid-19 in the trial. On Saturday, India reported 44,111 new Covid cases and 738 deaths. The recovery rate further jumped to 97.06% with 2,29,05,779 recoveries.

Last month, vaccine maker AstraZeneca also said its vaccine was effective against the Delta and Kappa variants, citing a study.

India has been administering the AstraZeneca vaccine, made domestically by the Serum Institute of India, which plans to step up monthly production from July to nearly 100 million doses.

Bharat Biotech now estimates it will make 23 million doses a month. The Phase-III data came as Ocugen Inc, which is co-developing Covaxin with Bharat Biotech for the US market, prepares to file a request for full US approval.

India, with a tally of 30.45 million infections, is the second most affected nation after the United States, with 33 million. The south Asian nation’s death toll has now crossed 400,000.